reports
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Tri...
Greenwich LifeSciences Announces Expansion of Flamingo-01 Clinical Trial to Ireland STAFFORD, Texas, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the expansion of FLAMINGO-01 clinical trial to Ireland. The Company's application to European regulators has been formally approved, adding Ireland as an approved country in FLAMINGO-01 in addition t...
Biodesix Announces One-for-Twenty Reverse Stock Split
Biodesix Announces One-for-Twenty Reverse Stock Split LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix” or the “Company”), a leader in personalized diagnostics, today announced a one-for-twenty reverse stock split (the “Reverse Stock Split”) of the Company’s common stock, par value $0.001, which will become effective at 12:01 a.m. Eastern Time on Monday, September 15, 2025. The Company’s common stock will continue to trade under Biodesix’s existing trading symbol, BDSX, on the Nasdaq Global Market (“Nasdaq”) on a split-adjusted basis when the ...
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation
Greenwich LifeSciences’ GLSI-100 Granted US FDA Fast Track Designation STAFFORD, Texas, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that FDA has granted Fast Track designation for GLSI-100 in the HLA-A*02 patient population. The designation specifically states that "GLSI-100 for the treatment of patients with HLA-A*02 genotype and HER2-positi...
- Jonathan Moreland
PRGO PERRIGO CO. PLC
POST POST HOLDINGS INC.
LKQ LKQ CORPORATION
ICUI ICU MEDICAL INC.
HBNC HORIZON BANCORP INC
EMN EASTMAN CHEMICAL COMPANY
D DOMINION ENERGY INC
CPRX CATALYST PHARMACEUTICALS
COTY COTY INC. CLASS A
ASYS AMTECH SYSTEMS INC.
AROW ARROW FINANCIAL CORP.
RLMD RELMADA THERAPEUTICS
QRHC QUEST RESOURCE HOLDING
GLO CLOUGH GLOBAL OPPORTUNITIES FUND
NTLA INTELLIA THERAPEUTICS INC.
MX MAGNACHIP SEMICONDUCTOR CORP.
NWPP NEW PEOPLES BANKSHARES INC.
BHR BRAEMAR HOTELS & RESORTS
CCEL CRYO-CELL INTERNATIONAL
REZI RESIDEO TECHNOLOGIES
WU INC.
AVTR THE WESTERN UNION COMPANY
SELF AVANTOR
PGEN INC.
COO SELF STORAGE GROUP
REYN INC.
STTK PRECIGEN INC
ENOV THE COOPER COMPANIES INC.
BLIN REYNOLDS CONSUMER PRODUCTS INC.
EBC SHATTUCK LABS
NRGV ENOVIS CORPORATION
ONL BRIDGELINE DIGITAL INC
OBIO EASTERN BANKSHARES INC
ET ENERGY VAULT HOLDINGS INC
PROP ORION OFFICE REIT INC
BKKT ORCHESTRA BIOMED HOLDINGS INC
ISPO ENERGY TRANSFER LP
AFCG PRAIRIE OPERATING CO.
FG BAKKT HOLDINGS INC.
NIQ INSPIRATO INCORPORATED
STSS AFC GAMMA
FEAM INC.
SINT F AND G ANNUITIES AND LIFE
VWFB INC.
NIQ GLOBAL INTELLIGENCE PLC
SHARPS TECHNOLOGY INC.
5E ADVANCED MATERIALS INC.
SINTX TECHNOLOGIES INC.
VWF BANCORP
INC.
Biodesix to Participate in Lake Street Capital Markets’ 9th Annual Bes...
Biodesix to Participate in Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference LOUISVILLE, Colo., Sept. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Robin Cowie, Chief Financial Officer, will host in-person 1x1 investor meetings at Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference on Thursday, September 11, 2025. Lake Street Capital Markets’ 9th Annual Best Ideas Growth (BIG9) Conference Date: Thursday, September 11, 2025Location: New York, NY1x1 meetings only About Biodesix ...
- Jonathan Moreland
PRGO PERRIGO CO. PLC
POST POST HOLDINGS INC.
LKQ LKQ CORPORATION
ICUI ICU MEDICAL INC.
HBNC HORIZON BANCORP INC
EMN EASTMAN CHEMICAL COMPANY
DIN DINE BRANDS GLOBAL INC.
D DOMINION ENERGY INC
CPRX CATALYST PHARMACEUTICALS
COTY COTY INC. CLASS A
AROW ARROW FINANCIAL CORP.
RLMD RELMADA THERAPEUTICS
QRHC QUEST RESOURCE HOLDING
NTLA INTELLIA THERAPEUTICS INC.
MX MAGNACHIP SEMICONDUCTOR CORP.
ECIA ENCISION INC
UA UNDER ARMOUR
BHR INC.
CCEL BRAEMAR HOTELS & RESORTS
ULBI CRYO-CELL INTERNATIONAL
WU ULTRALIFE
AVTR THE WESTERN UNION COMPANY
SELF AVANTOR
PGEN INC.
REYN SELF STORAGE GROUP
OPCH INC.
ENOV PRECIGEN INC
BLIN REYNOLDS CONSUMER PRODUCTS INC.
EBC OPTION CARE HEALTH INC
NRGV ENOVIS CORPORATION
ONL BRIDGELINE DIGITAL INC
OBIO EASTERN BANKSHARES INC
ET ENERGY VAULT HOLDINGS INC
PROP ORION OFFICE REIT INC
BKKT ORCHESTRA BIOMED HOLDINGS INC
FIP ENERGY TRANSFER LP
ISPO PRAIRIE OPERATING CO.
AFCG BAKKT HOLDINGS INC.
ECF FTAI INFRASTRUCTURE INC
SST INSPIRATO INCORPORATED
STRZ AFC GAMMA
STSS INC.
FEAM ELLSWORTH FUND LTD
SINT SYSTEM1 INC
STARZ ENTERTAINMENT CORP
SHARPS TECHNOLOGY INC.
5E ADVANCED MATERIALS INC.
SINTX TECHNOLOGIES INC.
- Jonathan Moreland
Berkshire Hills Bancorp and Brookline Bancorp Receive Regulatory Appro...
Berkshire Hills Bancorp and Brookline Bancorp Receive Regulatory Approvals for Merger of Equals to form Beacon Financial Corporation All required regulatory approvals related to the proposed merger have been received.Proposed merger closing is expected to be completed effective September 1, 2025, subject to the satisfaction of the remaining customary closing conditions.Clients will continue to be served through their respective Berkshire Bank, Brookline Bank, Bank Rhode Island and PCSB Bank offices as divisions of Beacon Bank & Trust until systems conversion in 2026. BOSTON, Aug. 25, 2025...
Noble Capital Markets Initiates Equity Research Coverage on Greenwich ...
Noble Capital Markets Initiates Equity Research Coverage on Greenwich LifeSciences STAFFORD, Texas, Aug. 20, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced that Noble Capital Markets has initiated company-sponsored equity research coverage on the Company. The full report by Noble Capital Markets Research Analyst Robert LeBoyer is available : About FLAMING...
Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence...
Biodesix Recognized as a Thermo Fisher Scientific Center of Excellence (COE) for NGS Diagnostics Biodesix recently validated Thermo Fisher’s tissue-based Oncomine Dx Express Test for solid tumors on the Genexus Dx Integrated Sequencer LOUISVILLE, Colo., Aug. 19, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leader in personalized diagnostics, announced that the company is designated as a Thermo Fisher Scientific Center of Excellence (COE) as part of Thermo Fisher’s collaborative initiative to advance NGS-based diagnostics. The services provided to Thermo Fisher are an example of Biodesix ...
Greenwich LifeSciences Announces Plan to Build Out Internal Clinical O...
Greenwich LifeSciences Announces Plan to Build Out Internal Clinical Operations Team STAFFORD, Texas, Aug. 19, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced its plan to build out its internal clinical trial management and operations team. The Company has begun to hire its own staff to manage and operate FLAMINGO-01, while reducing its dependence on more ...
- Dave Nicoski
- Ross LaDuke
Vermilion Short Shots: Technically Vulnerable Stocks
Short Shots is a collection of technically vulnerable charts culled from the Negative Inflecting and Toppy columns within our Weekly Compass report or from various technical screening processes. The charts contained in this report have developed concerning technical patterns that suggest further price deterioration is likely. For these reasons Short Shots can also be a great source of ideas for investors interested in short-selling candidates.
PCTY PAYLOCITY HOLDING CORP.
LNTH LANTHEUS HOLDINGS INC
HUBS HUBSPOT INC.
HAE HAEMONETICS CORPORATION
CRM SALESFORCE.COM INC.
CRK COMSTOCK RESOURCES INC.
CPRX CATALYST PHARMACEUTICALS
AR ANTERO RESOURCES CORPORATION
HRB H&R BLOCK INC.
SNAP SNAP INC. CLASS A
CNX CNX RESOURCES CORPORATION
ACI-R-A ADRIATIC CROATIA INTERNATIONAL CLUB D.D.
HPK HIGHPEAK ENERGY INC (A)
ACVA ACV AUCTIONS INC
CHK CHESAPEAKE ENERGY CORP
BRZE BRAZE INC
SG SWEETGREEN INC
MNDY MONDAY COM LTD
IOT SAMSARA INC
KLC KINDERCARE LEARNING COS INC
TEAM ATLASSIAN CORPORATION
SLDE SLIDE INS HLDG INC
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania
Greenwich LifeSciences Announces Expansion of Flamingo-01 into Romania STAFFORD, Texas, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences, today announced the addition of clinical sites in Romania. The Company's application to expand Flamingo-01 into Romania has been formally approved by European regulators, thus adding Romanian sites to the approximately 150 approv...
Greenwich LifeSciences Provides Update on CEO Interviews & Corporate E...
Greenwich LifeSciences Provides Update on CEO Interviews & Corporate Events STAFFORD, Texas, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on the development of GLSI-100, an immunotherapy to prevent breast cancer recurrences in patients who have previously undergone surgery, today provided the following update on CEO interviews and corporate events. The following videos, which include CEO interviews, are now available on the Company’s website at the bottom of the Welcome page: Jun 28, 20...
Biodesix Announces Second Quarter 2025 Results and Highlights
Biodesix Announces Second Quarter 2025 Results and Highlights Q2 2025 Revenue of $20.0 million, an increase of 12% over Q2 2024; Q2 2025 gross profit margin of 80%, a 150-basis point improvement from Q2 2024; Reiterating FY2025 Total Revenue Guidance of $80-85 million; Conference Call and Webcast Today at 4:30 p.m. ET LOUISVILLE, Colo., Aug. 07, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced its financial and operating results for the second quarter ended June 30, 2025. “We had strong second qu...
Berkshire Hills Bancorp and Brookline Bancorp to be Combined as Beacon...
Berkshire Hills Bancorp and Brookline Bancorp to be Combined as Beacon Financial Corporation and Beacon Bank Upon the Closing of their Merger of Equals BOSTON, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Berkshire Hills Bancorp, Inc. (“Berkshire”) (NYSE: BHLB), the parent company of Berkshire Bank, and Brookline Bancorp, Inc. (“Brookline”) (NASDAQ: BRKL), the parent company of Brookline Bank, Bank Rhode Island, and PCSB Bank, today announced that the combined holding company that will be created through their transformative merger of equals will be named Beacon Financial Corporation and remain list...
Biodesix to Present at the Canaccord Genuity 45th Annual Growth Confer...
Biodesix to Present at the Canaccord Genuity 45th Annual Growth Conference BOULDER, Colo., Aug. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced Scott Hutton, Chief Executive Officer, and Robin Cowie, Chief Financial Officer, will present in a fireside chat and host in-person 1x1 investor meetings at the Canaccord Genuity 45th Annual Growth Conference on August 12, 2025. Canaccord Genuity 45th Annual Growth Conference Fireside Chat Date: Tuesday, August 12, 2025Fireside Chat Time: 4:30 PM ETLocation: Boston, MA The presentation wi...
Biodesix to Report Second Quarter 2025 Financial Results on August 7, ...
Biodesix to Report Second Quarter 2025 Financial Results on August 7, 2025 LOUISVILLE, Colo., July 24, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: BDSX), a leading diagnostic solutions company, today announced that it will release financial results for the second quarter ended June 30, 2025 after the close of trading on Thursday, August 7. Biodesix management will host a conference call and webcast to discuss its financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day. Listeners can register for the webcast via this . Analysts who wish to participate in t...
Brookline Bancorp Announces Second Quarter Results
Brookline Bancorp Announces Second Quarter Results Net Income of $22.0 million, EPS of $0.25 Quarterly Dividend of $0.135 BOSTON, July 23, 2025 (GLOBE NEWSWIRE) -- Brookline Bancorp, Inc. (NASDAQ: BRKL) (the “Company”) today announced net income of $22.0 million, or $0.25 per basic and diluted share, for the second quarter of 2025, compared to net income of $19.1 million, or $0.21 per basic and diluted share, for the first quarter of 2025, and $16.4 million, or $0.18 per basic and diluted share, for the second quarter of 2024. The Company reported operating earnings after tax (non-GAA...
Brookline Bancorp, Inc. Announces Second Quarter 2025 Earnings Release...
Brookline Bancorp, Inc. Announces Second Quarter 2025 Earnings Release Date and Conference Call BOSTON, July 07, 2025 (GLOBE NEWSWIRE) -- Brookline Bancorp, Inc. (NASDAQ: BRKL) announced today that it will report second quarter 2025 earnings at the close of business on Wednesday, July 23, 2025. Management will host a conference call to review this information at 1:30 PM Eastern Time on Thursday, July 24, 2025. Interested parties may listen to the call and view a copy of the Company’s Earnings Presentation by joining the call via /attendee/149362707. To listen to the call without access to...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.